Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1

Conditions

Lung Neoplasms 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Kidney Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 42Carboplatin 24Cyclophosphamide 20Paclitaxel 19Nivolumab 17Cisplatin 15fludarabine 14Gemcitabine 12aldesleukin 10Docetaxel 10Bevacizumab 9Magnetic Resonance Spectroscopy 8Trastuzumab 7Specimen Handling 7Drug Therapy 7Pemetrexed 6Oxaliplatin 6Ipilimumab 6Interleukin-2 6Fluorouracil 6Cetuximab 6Blood Specimen Collection 6sargramostim 5pegfilgrastim 5avelumab 5Topotecan 5Taxes 5Irinotecan 5palbociclib 4durvalumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Technetium Tc 99m Sestamibi × Thoracic × Clear all
NCT00069160 2012-10-12

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
48 enrolled 13 charts
GenitourinaryGynecologicThoracic

Uterine Cervical Neoplasms, Kidney Neoplasms, Lung Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡